The multifaceted use of Lactobacillus reuteri DSM 17938 in a pediatric clinic: a retrospective observational study


  • Dhanasekhar Kesavelu Consultant Paediatric Gastroenterologist, SS Childcare and Apollo Childrens Hospital, Chennai, India



Nutritional supplements, Height, Weight, Children, L. reuteri DSM17938, Probiotic


Background: Lactobacillus reuteri DSM 17938 is a well-studied probiotic which colonizes many mammals. In humans, L. reuteri is found in various body sites including the gastrointestinal tract, urinary tract, skin and breast milk. It fulfills all the prerequisites of being a good probiotic as described by the world gastroenterology organization.

Methods: This was a retrospective observational study, where a nutritional supplement L. reuteri DSM 17938 was given to 197 children, aged 0-16 years, along with normal diet. The participants were having complains of diarrhea, stomach pain and frequent hospitalization. Various parameters were recorded such as sex, age, anthropometry-weight and height (every visit), diagnosis, reason for outpatient visits and various demography including but not limited to- birthplace, current location, year in school, reason for hospital admission (if any). Paired t test was used to find difference in weight and height between each visit.

Results: A total of 118 subjects were included in the analysis. Five drops of nutritional supplement L. reuteri DSM 17938 was given. Supplementation of L. reuteri reduced the need for hospital admissions. 96% children did not require hospital admission. It improved the overall health of the children. There was a statistical significance in the height and weight between first and second visits (p<0.001). A 7.65% weight increase was noted in between first and second visit. A 2.32% height increase was seen between first and second visit.

Conclusions: L. reuteri DSM 17938 given as a nutritional supplement improved the health of the children and reduced the need for hospital admissions.



Solis B, Samartin S, Gomez S, Nova E, Rosa BDL, Marcos A. Probiotics as a help in children suffering from malnutrition and diarrhoea. Eur J Clin Nutr. 2002;56(3):S57-9.

Food and Agricultural Organisation-World Health Organisation. Joint FAO/WHO Expert Consultation. 2001. Evaluation of Health and Nutritional Properties of Probiotics in food including Powder Milk with Live Lactic Acid Bacteria. Available at: http://www.fao. org/3/a0512e/a0512e.pdf. Accessed on 3 June 2021.

He M, Yang YX, Han H, Men JH, Bian LH, Wang GD. Effects of yogurt supplementation on the growth of preschool children in Beijing suburbs. Biomed Environ Sci. 2005;18(3):192-7.

Scholz-Ahrens KE, Ade P, Marten B, Weber P, Timm W, Açil Y, et al. Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure. J Nutr. 2007;137:838-46.

Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;2010(11):003048.

Szajewska H, Kotowska M, Mrukowicz JZ, Arma M, Mikolajczyk W. Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr. 2001;138(3):361-5.

AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Evid Based Child Health. 2014;9(3):584-671.

Thomas DW, Greer FR. American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Gastroenterology H. Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics. 2010;126(6):1217-31.

Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in human health and diseases. Front Microbiol. 2018;9:757.

Lebeer S, Vanderleyden J, Keersmaecker SCD. Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev. 2008;72(4):728-64.

Szajewska H, Guarino A, Hojsak I, Indrio F, Kolacek S, Shamir R, et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN working group for probiotics and prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531-9.

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to Lactobacillus reuteri ATCC 55730 and decreasing potentially pathogenic intestinal microorganisms (ID 904) pursuant to article 13(1) of regulation (EC) No 1924/2006. EFSA J. 2009;7(9):1243.

Tubelius P, Stan V, Zachrisson A. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health. 2005;4:25.

Krumbeck JA, Marsteller NL, Frese SA, Peterson DA, Ramer‐Tait AE, Hutkins RW, Characterization of the ecological role of genes mediating acid resistance in Lactobacillus reuteri during colonization of the gastrointestinal tract. Environ Microbiol. 2016;18(7):2172-84.

Onubi OJ, Poobalan AS, Dineen B, Marais D, McNeill G. Effects of probiotics on child growth: a systematic review. J Health Popul Nutr. 2015;34:8.

Dinleyici EC, PROBAGE Study Group, Vandenplas Y. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr. 2014;103(7):300-5.

Urbańska M, Gieruszczak-Białek D, Szajewska H. Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for diarrhoeal diseases in children. Aliment Pharmacol Ther. 2016;43(10):1025-34.

Francavilla R, Lionetti E, Castellaneta S, Ciruzzi F, Indrio F, Masciale A, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs placebo in children with acute diarrhoea-a double-blind study. Aliment Pharmacol Ther. 2012;36(4):363-9.

Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, et al. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J). 2015;91(4):392-6.

Romano C, Ferrau V, Cavataio F, Iacono G, Spina M, Lionetti E, et al. Lactobacillus reuteri in children with functional abdominal pain (FAP). J Paediatr Child Health. 2014;50(10):68-71.

Fatheree NY, Liu Y, Taylor CM, Hoang TK, Cai C, Rahbar MH, et al. Lactobacillus reuteri for infants with colic: a double-blind, placebo-controlled, randomized clinical trial. J Pediatr. 2017;191:170-8.

Urbańska M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr. 2014;173(10):1327-37.

Agustina R, Bovee-Oudenhoven IM, Lukito W, Fahmida U, Rest OVD, Zimmermann MB, et al. Probiotics Lactobacillus reuteri DSM 17938 and Lactobacillus casei CRL 431 modestly increase growth, but not iron and zinc status, among Indonesian children aged 1-6 years. J Nutr. 2013;143(7):1184-93.

Kaban RK, Hegar B, Rohsiswatmo R, Rohsiswatmo R, Handryastuti S, Amelia N, et al. Lactobacillus reuteri DSM 17938 improves feeding intolerance in preterm infants. Pediatr Gastroenterol Hepatol Nutr. 2019;22(6):545-53.

Bharani R, Biswas A, Lee J, Tran LA, Pecquet S, Steenhout P. Normal growth of infants receiving an infant formula containing Lactobacillus reuteri, galacto-oligosaccharides, and fructo-oligosaccharide: a randomized controlled trial. Matern Health Neonatol Perinatol. 2015;1:9.

Hojsak I. Probiotics in children: what is the evidence? Pediatr Gastroenterol Hepatol Nutr. 2017;20(3):139-46.

Hojsak I, Fabiano V, Pop TL, Goulet O, Zuccotti GV, Çokuğraş FC, Guidance on the use of probiotics in clinical practice in children with selected clinical conditions and in specific vulnerable groups. Acta Paediatr. 2018;107(6):927-37.




How to Cite

Kesavelu, D. (2021). The multifaceted use of Lactobacillus reuteri DSM 17938 in a pediatric clinic: a retrospective observational study. International Journal of Basic & Clinical Pharmacology, 10(9), 1134–1142.



Original Research Articles